Literature DB >> 25502431

Genomic profiling of breast cancers.

Christina Curtis1.   

Abstract

PURPOSE OF REVIEW: To describe recent advances in the application of advanced genomic technologies towards the identification of biomarkers of prognosis and treatment response in breast cancer. RECENT
FINDINGS: Advances in high-throughput genomic profiling such as massively parallel sequencing have enabled researchers to catalogue the spectrum of somatic alterations in breast cancers. These tools also hold promise for precision medicine through accurate patient prognostication, stratification, and the dynamic monitoring of treatment response. For example, recent efforts have defined robust molecular subgroups of breast cancer and novel subtype-specific oncogenes. In addition, previously unappreciated activating mutations in human epidermal growth factor receptor 2 have been reported, suggesting new therapeutic opportunities. Genomic profiling of cell-free tumor DNA and circulating tumor cells has been used to monitor disease burden and the emergence of resistance, and such 'liquid biopsy' approaches may facilitate the early, noninvasive detection of aggressive disease. Finally, single-cell genomics is coming of age and will contribute to an understanding of breast cancer evolutionary dynamics.
SUMMARY: Here, we highlight recent studies that employ high-throughput genomic technologies in an effort to elucidate breast cancer biology, discover new therapeutic targets, improve prognostication and stratification, and discuss the implications for precision cancer medicine.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25502431      PMCID: PMC4497788          DOI: 10.1097/GCO.0000000000000145

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  42 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.

Authors:  Hege G Russnes; Hans Kristian Moen Vollan; Ole Christian Lingjærde; Alexander Krasnitz; Pär Lundin; Bjørn Naume; Therese Sørlie; Elin Borgen; Inga H Rye; Anita Langerød; Suet-Feung Chin; Andrew E Teschendorff; Philip J Stephens; Susanne Månér; Ellen Schlichting; Lars O Baumbusch; Rolf Kåresen; Michael P Stratton; Michael Wigler; Carlos Caldas; Anders Zetterberg; James Hicks; Anne-Lise Børresen-Dale
Journal:  Sci Transl Med       Date:  2010-06-30       Impact factor: 17.956

3.  Genetic and phenotypic diversity in breast tumor metastases.

Authors:  Vanessa Almendro; Hee Jung Kim; Yu-Kang Cheng; Mithat Gönen; Shalev Itzkovitz; Pedram Argani; Alexander van Oudenaarden; Saraswati Sukumar; Franziska Michor; Kornelia Polyak
Journal:  Cancer Res       Date:  2014-01-21       Impact factor: 12.701

4.  The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.

Authors:  Markus Wallwiener; Andreas Daniel Hartkopf; Irène Baccelli; Sabine Riethdorf; Sarah Schott; Klaus Pantel; Frederik Marmé; Christof Sohn; Andreas Trumpp; Brigitte Rack; Bahriye Aktas; Erich-Franz Solomayer; Volkmar Müller; Wolfgang Janni; Andreas Schneeweiss; Tanja Natascha Fehm
Journal:  Breast Cancer Res Treat       Date:  2012-12-28       Impact factor: 4.872

5.  The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma.

Authors:  Zsuzsanna Lichner; Andreas Scorilas; Nicole M A White; Andrew H Girgis; Lora Rotstein; Kimberly C Wiegand; Ashraf Latif; Christina Chow; David Huntsman; George M Yousef
Journal:  Am J Pathol       Date:  2013-02-12       Impact factor: 4.307

6.  Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.

Authors:  Kimberly C Wiegand; Anna F Lee; Osama M Al-Agha; Christine Chow; Steve E Kalloger; David W Scott; Christian Steidl; Sam M Wiseman; Randy D Gascoyne; Blake Gilks; David G Huntsman
Journal:  J Pathol       Date:  2011-05-18       Impact factor: 7.996

7.  Detection of circulating tumor DNA in early- and late-stage human malignancies.

Authors:  Chetan Bettegowda; Mark Sausen; Rebecca J Leary; Isaac Kinde; Yuxuan Wang; Nishant Agrawal; Bjarne R Bartlett; Hao Wang; Brandon Luber; Rhoda M Alani; Emmanuel S Antonarakis; Nilofer S Azad; Alberto Bardelli; Henry Brem; John L Cameron; Clarence C Lee; Leslie A Fecher; Gary L Gallia; Peter Gibbs; Dung Le; Robert L Giuntoli; Michael Goggins; Michael D Hogarty; Matthias Holdhoff; Seung-Mo Hong; Yuchen Jiao; Hartmut H Juhl; Jenny J Kim; Giulia Siravegna; Daniel A Laheru; Calogero Lauricella; Michael Lim; Evan J Lipson; Suely Kazue Nagahashi Marie; George J Netto; Kelly S Oliner; Alessandro Olivi; Louise Olsson; Gregory J Riggins; Andrea Sartore-Bianchi; Kerstin Schmidt; le-Ming Shih; Sueli Mieko Oba-Shinjo; Salvatore Siena; Dan Theodorescu; Jeanne Tie; Timothy T Harkins; Silvio Veronese; Tian-Li Wang; Jon D Weingart; Christopher L Wolfgang; Laura D Wood; Dongmei Xing; Ralph H Hruban; Jian Wu; Peter J Allen; C Max Schmidt; Michael A Choti; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Luis A Diaz
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

8.  Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy.

Authors:  Cigall Kadoch; Diana C Hargreaves; Courtney Hodges; Laura Elias; Lena Ho; Jeff Ranish; Gerald R Crabtree
Journal:  Nat Genet       Date:  2013-05-05       Impact factor: 38.330

9.  Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

Authors:  François-Clément Bidard; Dieter J Peeters; Tanja Fehm; Franco Nolé; Rafael Gisbert-Criado; Dimitrios Mavroudis; Salvatore Grisanti; Daniele Generali; Jose A Garcia-Saenz; Justin Stebbing; Carlos Caldas; Paola Gazzaniga; Luis Manso; Rita Zamarchi; Angela Fernandez de Lascoiti; Leticia De Mattos-Arruda; Michail Ignatiadis; Ronald Lebofsky; Steven J van Laere; Franziska Meier-Stiegen; Maria-Teresa Sandri; Jose Vidal-Martinez; Eleni Politaki; Francesca Consoli; Alberto Bottini; Eduardo Diaz-Rubio; Jonathan Krell; Sarah-Jane Dawson; Cristina Raimondi; Annemie Rutten; Wolfgang Janni; Elisabetta Munzone; Vicente Carañana; Sofia Agelaki; Camillo Almici; Luc Dirix; Erich-Franz Solomayer; Laura Zorzino; Helene Johannes; Jorge S Reis-Filho; Klaus Pantel; Jean-Yves Pierga; Stefan Michiels
Journal:  Lancet Oncol       Date:  2014-03-11       Impact factor: 41.316

Review 10.  Implications of intratumour heterogeneity for treatment stratification.

Authors:  Andrew Crockford; Mariam Jamal-Hanjani; James Hicks; Charles Swanton
Journal:  J Pathol       Date:  2014-01       Impact factor: 7.996

View more
  10 in total

Review 1.  Signatures of breast cancer metastasis at a glance.

Authors:  George S Karagiannis; Sumanta Goswami; Joan G Jones; Maja H Oktay; John S Condeelis
Journal:  J Cell Sci       Date:  2016-04-15       Impact factor: 5.285

Review 2.  Molecular strategies in the management of bronchopulmonary and thymic neuroendocrine neoplasms.

Authors:  Irvin M Modlin; Mark Kidd; Pier-Luigi Filosso; Matteo Roffinella; Anna Lewczuk; Jaroslaw Cwikla; Lisa Bodei; Agnieska Kolasinska-Cwikla; Kyung-Min Chung; Margot E Tesselaar; Ignat A Drozdov
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 3.  Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker.

Authors:  Mersedeh Rohanizadegan
Journal:  Cancer Genet       Date:  2018-02-24

4.  Cell cycle gene expression networks discovered using systems biology: Significance in carcinogenesis.

Authors:  Robert E Scott; Prachi N Ghule; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2015-10       Impact factor: 6.384

5.  High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers.

Authors:  Scooter Willis; Yuliang Sun; Mark Abramovitz; Teng Fei; Brandon Young; Xiaoqian Lin; Min Ni; Justin Achua; Meredith M Regan; Kathryn P Gray; Robert Gray; Victoria Wang; Bradley Long; Roswitha Kammler; Joseph A Sparano; Casey Williams; Lori J Goldstein; Roberto Salgado; Sherene Loi; Giancarlo Pruneri; Giuseppe Viale; Myles Brown; Brian Leyland-Jones
Journal:  JCO Precis Oncol       Date:  2017-10-13

Review 6.  The application of radiomics in predicting gene mutations in cancer.

Authors:  Yana Qi; Tingting Zhao; Mingyong Han
Journal:  Eur Radiol       Date:  2022-01-20       Impact factor: 5.315

Review 7.  Profiling of Invasive Breast Carcinoma Circulating Tumour Cells-Are We Ready for the 'Liquid' Revolution?

Authors:  Marcin Braun; Aleksandra Markiewicz; Radzisław Kordek; Rafał Sądej; Hanna Romańska
Journal:  Cancers (Basel)       Date:  2019-01-25       Impact factor: 6.639

8.  Identification of Alternatively-Activated Pathways between Primary Breast Cancer and Liver Metastatic Cancer Using Microarray Data.

Authors:  Limei Wang; Jin Li; Enze Liu; Garrett Kinnebrew; Xiaoli Zhang; Daniel Stover; Yang Huo; Zhi Zeng; Wanli Jiang; Lijun Cheng; Weixing Feng; Lang Li
Journal:  Genes (Basel)       Date:  2019-09-25       Impact factor: 4.096

9.  Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.

Authors:  Zhi Hu; Jian-Hua Mao; Christina Curtis; Ge Huang; Shenda Gu; Laura Heiser; Marc E Lenburg; James E Korkola; Nora Bayani; Shamith Samarajiwa; Jose A Seoane; Mark A Dane; Amanda Esch; Heidi S Feiler; Nicholas J Wang; Mary Ann Hardwicke; Sylvie Laquerre; Jeff Jackson; Kenneth W Wood; Barbara Weber; Paul T Spellman; Samuel Aparicio; Richard Wooster; Carlos Caldas; Joe W Gray
Journal:  Breast Cancer Res       Date:  2016-07-01       Impact factor: 6.466

10.  EGFR-Based Immunoisolation as a Recovery Target for Low-EpCAM CTC Subpopulation.

Authors:  Ana Vila; Miguel Abal; Laura Muinelo-Romay; Carlos Rodriguez-Abreu; José Rivas; Rafael López-López; Clotilde Costa
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.